Additionally, AKT–mammalian targeting of rapamycin pathway activation and increased BIM expression have been suggested as possible mechanisms for increased PD-L1 expression in EGFR-mutant NSCLC [117,118]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.